Copy Link Print Information

Sivelestat

(Synonyms: EI546; LY544349; ONO5046)
31 Cited Publications
Revisión del cliente

Based on 31 publication(s) in Google Scholar

Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.68%
  • No. CAS: 127373-66-4
  • Fòrmula: C20H22N2O7S
  • Peso molecular:434.46
  • Almacenamiento:

    4°C, protect from light

    * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

  • Sivelestat Chemical Structure
    Sivelestat Chemical Structure
  • Experimental Validation Results for Sivelestat
  • Experimental Validation Results for Sivelestat
  • Experimental Validation Results for Sivelestat
  • Experimental Validation Results for Sivelestat
  • Experimental Validation Results for Sivelestat
No. CAS: 127373-66-4
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Sivelestat:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Sivelestat

More
Customer Validation & Images
Flow CytometryIn Vivo Efficacy StudyIn Vivo Imaging
  • Flow Cytometry
  • In Vivo Efficacy Study
  • In Vivo Imaging
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Sivelestat Chemical Structure
    Sivelestat Chemical Structure
    1/16
  • 1/16

    Sivelestat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 5;16(1):1378. [Abstract]

    Customer Validation
     To evaluate this specific effect of NETosis in the Brd7-deficient context, we treated the mice injected with Brd7-KO cells with either Sivelestat (50 mg/kg) or DMSO starting at the 2-week timepoint, which marks the onset of lung metastatic outgrowth. FACS analysis of dissociated lungs isolated at the 4-week timepoint demonstrated a significant decrease in CTLA4 + CD8 + and PD1 + CD8 + T cells upon Sivelestat treatment.

  • 1/16

    Sivelestat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 5;16(1):1378. [Abstract]

    Customer Validation
     To evaluate this specific effect of NETosis in the Brd7-deficient context, we treated the mice injected with Brd7-KO cells with either Sivelestat (50 mg/kg) or DMSO starting at the 2-week timepoint, which marks the onset of lung metastatic outgrowth.

  • 1/16

    Sivelestat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 5;16(1):1378. [Abstract]

    Customer Validation
     The mice injected with the 4T07-TGL-Brd7 KO cells (Day 0) were i.p. injected with Sivelestat (50 mg/kg) or DMSO control on days -5,-3,-1,1 and on every alternate day thereafter until Week 4. Represent bioluminescence images for the indicated murine cohorts at 30 min, 1 week, and 4 weeks post tumor cell injection.

  • 1/16

    Sivelestat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 5;16(1):1378. [Abstract]

    Customer Validation
     The mice injected with the 4T07-TGL-Brd7 KO cells (Day 0) were i.p. injected with Sivelestat (50 mg/kg) or DMSO control on days -5,-3,-1,1 and on every alternate day thereafter until Week 4. Line graph showing the normalized photon flux for the indicated murine cohorts over time.

  • 1/16

    Sivelestat purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Sep;57(9):2067-2082. [Abstract]

    Customer Validation
     Sivelestat treatment selectively modulates innate immune cell populations in lung and spleen. Data on weight change in the untreated group (infected with SARS-CoV-2 only) and the Sivelestat (10 mg/kg/day, 50 μL, intraperitoneally)/2% DMSO saline treatment group.

  • Sivelestat